The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States

ConclusionsIbalizumab may represent a cost-effective and affordable option to improve health outcomes for individuals with MDR HIV-1 infection.
Source: PharmacoEconomics - Category: Health Management Source Type: research